SiBone (NASDAQ:SIBN) CEO Laura Francis Sells 51,884 Shares of Stock

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 51,884 shares of SiBone stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $19.46, for a total value of $1,009,662.64. Following the sale, the chief executive officer directly owned 321,386 shares in the company, valued at approximately $6,254,171.56. This trade represents a 13.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Laura Francis also recently made the following trade(s):

• On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total value of $78,538.46.

SiBone Stock Performance

Shares of SIBN stock traded up $0.48 during mid-day trading on Friday, reaching $19.96. The stock had a trading volume of 1,290,316 shares, compared to its average volume of 620,561. SiBone has a one year low of $11.48 and a one year high of $21.89. The firm has a market cap of $885.21 million, a PE ratio of -58.71 and a beta of 0.66. The firm’s 50 day simple moving average is $17.40 and its 200 day simple moving average is $15.30. The company has a quick ratio of 7.55, a current ratio of 9.15 and a debt-to-equity ratio of 0.20.

SiBone (NASDAQ:SIBN) last released its quarterly earnings data on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.06. The business had revenue of $56.01 million for the quarter, compared to analysts’ expectations of $55.34 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. On average, analysts forecast that SiBone will post -0.4 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on SIBN. Truist Financial restated a “buy” rating and issued a $23.00 price objective (up from $21.00) on shares of SiBone in a research note on Tuesday, August 4th. UBS Group lifted their target price on shares of SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Weiss Ratings raised shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. Finally, TD Cowen increased their price target on shares of SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $24.17.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. ANTIPODES PARTNERS Ltd acquired a new stake in shares of SiBone in the 4th quarter valued at $29,000. Versant Capital Management Inc increased its position in shares of SiBone by 102.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock worth $29,000 after purchasing an additional 887 shares in the last quarter. Royal Bank of Canada increased its position in shares of SiBone by 98.5% during the 4th quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock worth $29,000 after purchasing an additional 736 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in SiBone by 64,700.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock valued at $38,000 after purchasing an additional 1,941 shares during the last quarter. Finally, Kemnay Advisory Services Inc. bought a new position in SiBone during the 4th quarter valued at about $53,000. 98.11% of the stock is currently owned by institutional investors and hedge funds.

About SiBone

Si-BONE, Inc is a commercial?stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA?cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.